Uveal Melanoma: Sequencing Therapy

Source: OncLive, August 2021

Richard D. Carvajal, MD: You presented nice work trying to tease out the potential confounding effects of post-progression therapies.

Marlana M. Orloff, MD: This takes us back to an abstract at ASCO 2019 [American Society of Clinical Oncology meeting] where we had observed, and I guess it was how many patients. It was ultimately about 29 patients from a couple of our institutions.

READ THE ORIGINAL FULL ARTICLE